Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued strong uptake of Eylea in Europe threatens Lucentis’s historical position as the patient-share leader in this market, while use of off-label Avastin differs across the EU5 countries. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Dry and Wet Age-Related Macular Degeneration Current Treatment EU offers a snapshot of how EU5 ophthalmologists are currently managing their dry and wet AMD patients, with a particular focus on the use of anti-VEGF for wet AMD, as well as insight into the factors driving such prescribing habits.

Table of contents

  • Dry And Wet Age-Related Macular Degeneration - Current Treatment - Detailed Expanded Analysis (EU)

Author(s): Sarah Soucy

Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.

Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


Related Reports

Dry And Wet Age-Related Macular Degeneration - Landscape & Forecast - Disease Landscape & Forecast

The wet age-related macular degeneration (AMD) therapy market has long been dominated by three

View Details

Dry And Wet Age-Related Macular Degeneration - Special Topics - Dry And Wet Age-Related Macular Degeneration | Special Topics | Beovu: Nine Months Postlaunch For Wet AMD | US | 2020

Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of...

View Details

Dry And Wet Age-Related Macular Degeneration - Special Topics - Special Topics - Beovu - Three Months Postlaunch For Wet AMD (US)

Novartis’s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment...

View Details

Dry And Wet Age-Related Macular Degeneration - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key 

View Details